Vincent Bours

Prof. Dr. Vincent Bours


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2020 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
PDF file
MAMaria Artesi
Maria Artesi
SBSébastien Bontems
Sébastien Bontems
PGPaul Göbbels
Paul Göbbels
MFMarc Franckh
Marc Franckh
PMPiet Maes
Piet Maes
KDKeith Durkin
Keith Durkin
Control of the ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic requires accurate laboratory testing to identify infected individuals while also clearing essential staff to continue to work. At the current time, a number of quantitative real-time PCR (qRT-PCR) assays have been developed to identify SARS-CoV-2, targeting multiple positions in the viral genome. While the mutation rate of SARS-CoV-2 is moderate, given the large number of transmission chains, it is prudent to monitor circulating viruses for variants that might compromise these assays.

Verified
Journal Article
Open access
PDF file
SSSylvie Streel
Sylvie Streel
ASAlixe Salmon
Alixe Salmon
Adriane DHEURAdriane DHEUR
Adriane DHEUR
VBVincent Bours
Vincent Bours
NLNatacha Leroi
Natacha Leroi
CGChristine Gennigens
Christine Gennigens
Molecular algorithms may estimate the risk of recurrence and death for patients with endometrial cancer (EC) and may impact treatment decisions. To detect microsatellite instabilities (MSI) and p53 mutations, immunohistochemistry (IHC) and molecular techniques are used. To select the most appropriate method, and to have an accurate interpretation of their results, knowledge of the performance characteristics of these respective methods is essential. The objective of this study was to assess the diagnostic performance of IHC versus molecular techniques (gold standard). One hundred and thirty-two unselected EC patients were enrolled in this study. Agreement between the two diagnostic methods was assessed using Cohen’s kappa coefficient. Sensitivity, specificity, positive (PPV) and negative predictive values (NPV) of the IHC were calculated. For MSI status, the sensitivity, specificity, PPV and NPV were 89.3%, 87.3%, 78.1% and 94.1%, respectively. Cohen’s kappa coefficient was 0.74. For p53 status, the sensitivity, specificity, PPV, and NPV were 92.3%, 77.1%, 60.0% and 96.4%, respectively. Cohen’s kappa coefficient was 0.59. For MSI status, IHC presented a substantial agreement with the polymerase chain reaction (PCR) approach. For the p53 status, the moderate agreement observed between IHC and next generation sequencing (NGS) methods implies that they cannot be used interchangeably.

Verified
Journal Article
Open access
PDF file
ALAimé Zola Lumaka
Aimé Zola Lumaka
CFCorinne Fasquelle
Corinne Fasquelle
FDFrançois-Guillaume Debray
François-Guillaume Debray
SASerpil Alkan
Serpil Alkan
AJAdeline Jacquinet
Adeline Jacquinet
VBVincent Bours
Vincent Bours
Rapid Whole Genome Sequencing (rWGS) represents a valuable exploration in critically ill pediatric patients. Early diagnosis allows care to be adjusted. We evaluated the feasibility, turnaround time (TAT), yield, and utility of rWGS in Belgium. Twenty-one unrelated critically ill patients were recruited from the neonatal intensive care units, the pediatric intensive care unit, and the neuropediatric unit, and offered rWGS as a first tier test. Libraries were prepared in the laboratory of human genetics of the University of Liège using Illumina DNA PCR-free protocol. Sequencing was performed on a NovaSeq 6000 in trio for 19 and in duo for two probands. The TAT was calculated from the sample reception to the validation of results. Clinical utility data were provided by treating physicians. A definite diagnosis was reached in twelve (57.5%) patients in 39.80 h on average (range: 37.05–43.7). An unsuspected diagnosis was identified in seven patients. rWGS guided care adjustments in diagnosed patients, including a gene therapy, an off-label drug trial and two condition-specific treatments. We successfully implemented the fastest rWGS platform in Europe and obtained one of the highest rWGS yields. This study establishes the path for a nationwide semi-centered rWGS network in Belgium.

15 August 2012 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
ETEmilie Théâtre
Emilie Théâtre
KFKim Frederix
Kim Frederix
WGWilliam Guilmain
William Guilmain
CDCéline Delierneux
Céline Delierneux
CLChristelle Lecut
Christelle Lecut
COCécile Oury
Cécile Oury
In airways, the ecto-nucleoside triphosphate diphosphohydrolase CD39 plays a central role in the regulation of physiological mucosal nucleotide concentrations and likely contributes to the control of inflammation because accelerated ATP metabolism occurs in chronic inflammatory lung diseases. We sought to determine whether constant elevated CD39 activity in lung epithelia is sufficient to cause inflammation and whether this affects the response to acute LPS or Pseudomonas aeruginosa exposure. We generated transgenic mice overexpressing human CD39 under the control of the airway-specific Clara cell 10-kDa protein gene promoter. Transgenic mice did not develop any spontaneous lung inflammation. However, intratracheal instillation of LPS resulted in accelerated recruitment of neutrophils to the airways of transgenic mice. Macrophage clearance was delayed, and the amounts of CD8+ T and B cells were augmented. Increased levels of keratinocyte chemoattractant, IL-6, and RANTES were produced in transgenic lungs. Similarly, higher numbers of neutrophils and macrophages were found in the lungs of transgenic mice infected with P. aeruginosa, which correlated with improved bacteria clearance. The transgenic phenotype was partially and differentially restored by coinstillation of P2X1 or P2X7 receptor antagonists or of caffeine with LPS. Thus, a chronic increase of epithelial CD39 expression and activity promotes airway inflammation in response to bacterial challenge by enhancing P1 and P2 receptor activation.

9 August 2020 in Discover Oncology
Verified
Journal Article
Closed access
PDF file
JUJeanne P. Uyisenga
Jeanne P. Uyisenga
YBYvan Butera
Yvan Butera
ADAhmed Debit
Ahmed Debit
CJClaire Josse
Claire Josse
CACostas C. Ainhoa
Costas C. Ainhoa
VBVincent Bours
Vincent Bours

20 October 2022 in Viruses
Verified
Journal Article
Open access
PDF file
LCLize Cuypers
Lize Cuypers
SDSimon Dellicour
Simon Dellicour
SHSamuel Hong
Samuel Hong
BPBarney I. Potter
Barney I. Potter
BVBruno Verhasselt
Bruno Verhasselt
GBGuy Baele
Guy Baele
An adequate SARS-CoV-2 genomic surveillance strategy has proven to be essential for countries to obtain a thorough understanding of the variants and lineages being imported and successfully established within their borders. During 2020, genomic surveillance in Belgium was not structurally implemented but performed by individual research laboratories that had to acquire the necessary funds themselves to perform this important task. At the start of 2021, a nationwide genomic surveillance consortium was established in Belgium to markedly increase the country’s genomic sequencing efforts (both in terms of intensity and representativeness), to perform quality control among participating laboratories, and to enable coordination and collaboration of research projects and publications. We here discuss the genomic surveillance efforts in Belgium before and after the establishment of its genomic sequencing consortium, provide an overview of the specifics of the consortium, and explore more details regarding the scientific studies that have been published as a result of the increased number of Belgian SARS-CoV-2 genomes that have become available.